Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
Authors
Keywords
-
Journal
GROWTH FACTORS
Volume 33, Issue 2, Pages 113-127
Publisher
Informa UK Limited
Online
2015-02-20
DOI
10.3109/08977194.2015.1010643
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer
- (2014) Huai-Qing Luo et al. Asian Pacific Journal of Cancer Prevention
- Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis
- (2014) Xuanzhang Huang et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
- (2013) Donald Richards et al. EUROPEAN JOURNAL OF CANCER
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- (2013) Thomas Crosby et al. LANCET ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis
- (2013) Wei Tian et al. PANCREATOLOGY
- Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses
- (2013) Nikola Panic et al. PLoS One
- Radiotherapy for gastric cancer: a systematic review and meta-analysis
- (2013) Xiaohui Pang et al. TUMOR BIOLOGY
- Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
- (2013) Silvy Laporte et al. BMJ Open
- Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
- (2012) Geoffrey Y. Ku et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis
- (2011) Peng Chen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
- (2010) Yelena Y. Janjigian et al. Journal of Thoracic Oncology
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
- (2009) S. Lorenzen et al. ANNALS OF ONCOLOGY
- Evidence on the use of platelet-rich plasma for diabetic ulcer: A systematic review
- (2009) Diana Lima Villela et al. GROWTH FACTORS
- Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials
- (2008) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started